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Purpose: Urokinase is used clinically for thrombolysis, but little is known of its direct 
effect on vascular endothelial cells. The following experiments were preformed to assess the in 
vitro effects of urokinase on vascular endothelial cell growth, adhesion molecule xpression, 
and interaction with lymphocytes, polymorphonudear leukocytes, and platelets. 
Methods: Commercially available human umbilical vein endothelial cells (HUVEC) were 
cultured with varying concentrations of urokinase (0 to 10,000 IU /ml )  (clinical dosage, 
---500 IU/ml) .  HUVEC viability was determined from 1 to 4 days. HUVECs were 
incubated with urokinase (0 to 2000 IU /ml )  from 4 to 72 hours. Adherence of
Sl-chromium-labeled polymorphonuclear leukocytes, platelets, or lymphocytes was then 
quantitated. In separate xperiments HUVEC adhesion molecule xpression (intercellu- 
lar adhesion molecule-I, vascular cell adhesion molecule-I, or endothelial leukocyte 
adhesion molecule-1) was determined by flow cytometry. 
Results: There was a decrease of HUVEC viability at suprapharmacologic urokinase 
concentrations of -----2000 IU /ml  compared with nontreated control samples (0 IU/ml ,  
73% + 2%, 2000 IU/ml ,  60.5% --- 1.9%, p < 0.05) presumably because of drug toxicity. 
There was no significantly increased polymorphonuclear leukocyte, lymphocyte, or plate~ 
let adhesion to urokinase-treated HUVEC monolayers at any time point. This was also 
true for each adhesion molecule tested. 
Conclusions: Urokinase at clinically relevant concentrations (-<500 IU /ml )  did not affect 
endothelial cell viability or growth, nor did it upregulate adhesion molecule xpression or 
cellular adhesion associated with the local vascular inflammatory esponse. It is therefore 
implied that the use of urokinase in vivo similarly would not initiate the vascular 
inflammatory esponse. (J Vase Surg 1997;25:471-80.) 
Lyric therapy for thromboembolic arterial disease 
including that of arterial bypass grafts increased in 
use after McNamara and Fischer published their 
1985 results with uroldnase infusions to reestablish 
patency of occluded vessels. 1,2 Since then several pro- 
tocol modifications have been made, resulting in 
improved thrombolysis rates. 3,4 After successful 
thrombolysis is performed, surgical intervention to 
correct or bypass atherosclerotic segments i usually 
required to maintain long-term patency. 1 
Research into atherosclerotic disease has demon- 
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strated the active role that vascular endothelial cells 
play in the modulation of the local inflammatory 
response. However, any effect that this urokinase 
treatment has on the vascular endothelial inflamma- 
tory response isnot known. Vascular endothelial cells 
have been shown to express cell surface adhesion 
molecules that act to recruit polymorphonuclear leu- 
kocytes (PMNs), lymphocytes, and platelets to areas 
of  damage and inflammation.5-9 Inflammatory cyto- 
kines such as interleuldn-1, tumor necrosis factor-s, 
lymphotoxin, and bacterial lipopolysaccharide (LPS) 
produce upregulation of endothelial leukocyte adhe- 
sion molecule- 1 (ELAM- 1), vascular cell adhesion 
molecule- 1 (VCAM- 1), and intercellular adhesion 
molecule- 1 (I CAM- 1 ), all of  which will in turn bind 
the previously mentioned leukocytes. 1°d6 Endoge- 
nous hematologic omponents uch as thrombin 
have also been shown to increase both neutrophil 
and mononuclear cell adhesion to VECs in vitro. 17,]8 
It is believed that these endothelial adhesive pro- 
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Fig. 1. Effects Of urokinase on endothelial cell viability at 1 to 4 days. There was significantly 
decreased viability (/x = p < 0.05 vs 0 IU/ml) at supratherapeutic urokinase concentrations of 
2000 to 10,000 IU/ml by 4 days of treatment, n = 3 for each point. 
cesses may represent some of the initial steps leading 
to resultant neointimal hyperplasia. One example of 
in vivo evidence for this includes the upregulation of 
ICAM- 1 demonstrated in atherosclerotic plaques.19~° 
In vitro research involving urokinase to date has 
focused on endogenously produced urokinase, its 
various forms, and its receptor. Urokinase is synthe- 
sized by VECs, which also express a cell surface 
receptor for it. 2123 Urokinase xpression is inducible 
by inflammatory cytokines uch as tumor necrosis 
factor-~ and basic fibroblast growth factor and has a 
role in endothelial cell migration in endothelial 
wound models. 24-26 The high molecule weight, sin- 
gle-chain form of urokinase has also been demon- 
strated to contain an epidermal growt h factor do- 
main that is mitogenic. 27 
Despite these significant effects of endogenously 
produced urokinase on VECs at very low concentra- 
tions, no data exist on the effects of exogenously 
administered urokinase at higher, clinically relevant 
doses (i.e., -<500 IU/ml).  2829 The following exper- 
iments were designed to evaluate how exogenously 
administered urokinase in vitro affects VECs adhe- 
sion of the cellular components of the local inflam- 
matory process. 
MATERIAL  AND METHODS 
Endothelial cell culture. Human umbilical vein 
endothelial cells (HUVEC) were purchased from 
American Type Culture Collection (Rockville, Md.) 
and maintained on Primaria 100 mm Petri dishes 
(Falcon Plastics, Oxnard, Calif.) in MCDB 105 (Sig- 
ma Chemical, St. Louis, Mo.), 60 ~g/ml  endothelial 
cell growth supplement (Sigma Chemical), 20 U /ml  
porcine heparin, and 10% fetal calf serum (FCS) 
(GIBCO, Grand Island, N.Y.). Petri dishes were in- 
cubated at 37 ° C in 5% CO 2. Cells were fed twice a 
week. HUVECs grew to confluence by 1 week and 
were harvested with 0.05% trypsin (0.25% trypsin, 
0.02% ethylenediaminetetraacetic acid, 1:4, Sigma 
Chemical) for 5 to 8 minutes at 37 ° C. HUVECs 
demonstrated typical morphologic characteristics 
and exhibited positive staining for von Willibrand's 
factor as described by Jaffe et al.30-32 
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Fig. 2. Effect ofurokinase on endothelial cell growth. At therapeutic urokinase doses (-<500 
IU/mL), there were no deleterious effects on HUVEC cell growth. Doubling times could not 
be calculated for 5000 or 10,000 IU/ml because of cytopathic effects at these concentrations. 
n= 3, p = NS. 
Growth and viability. HUVECs were growth- 
arrested by incubating them in MCDB 105 and 0.4% 
FCS for 48 hours at 37 ° C. HUVECs were plated 
into 24-well Primaria plates at 0.4 × 104 cells per 
well. Uroldnase obtained as a gift from Abbott Lab- 
oratories (Abbott Laboratories, Abbott Park, Ill.) 
was added to each well to give final concentrations 
from 0 to 10,000 IU/ml .  Plates were then incubated 
at 37 ° C in 5% CO 2 for 1 to 4 days. On the appropri- 
ate day the cells were harvested as previously de- 
scribed, and cell number and viability were deter- 
mined by trypan blue exclusion. Doubling time was 
calculated with the following equation: doubling 
time = (log2) × (t2 - t l ) / ( log  n2 - log  nl) ,where 
t represents ime in hours and n is cell number. 
Adhesion assays. The HUVEC/leukocyte ad- 
hesion protocol was a modification of those used by 
Kyan-Aung et al.6 and Cavender et al? 3 HUVECs 
were plated into 24-well Primaria plates at 0.1 × 106 
cells per well in MCDB 105 and 10% FCS. Urokinase 
was added to each well to give final concentrations 
from 0 to 2000 IU/ml .  Lipopolysaccharide (LPS) 
was used as a positive control, because it is known to 
upregulate HUVEC adhesion molecule expression 
with resultant leukocyte adhesion, s 11,12,16 LPS final 
concentration was 5 ~g/ml.  Plates were incubated at 
37 ° C in 5% CO 2 for 4, 24, 48, or 72 hours. At the 
appropriate time the urokinase containing media was 
aspirated out, and the plates were washed with 
MCDB 105 and 10% FCS. 
PMNs, lymphocytes, and platelets were isolated 
from healthy volunteer donors. Whole blood was 
collected in citrated tubes and then layered onto 
"i-Step Platelet" centrifuge gradient (Accurate 
Chemical, Westbury, N. Y.). This was spun at 350g 
for 15 minutes at 20 ° C. The platelet band was re- 
moved and washed with D-PBS- ( -Ca++,  
-Mg++)  followed by D-PBS- and 10% FCS. The 
buffy coat layer from the "l-Step Platelet" gradient 
was then layered onto the "Polymorph" gradient 
(Accurate Chemical, Westbury, N.Y.) and spun at 
400g for 30 minutes at 20 ° C. Polymorphonuclear 
bands and mononuclear bands (containing almost 
exclusively mphocytes) were isolated and washed as 
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Fig. 3. Relative adhesion of  lymphocytes to HUVEC monolayers in face of urokinase (0 to 
2000 IU /ml )  or LPS (5 jxg/ml) for 4, 24, 48, or 72 hours. Nontreated controls (0 IU /ml )  
were defined as 100%. Only LPS-stimulated HUVECs  demonstrated significantly increased 
adhesion. § = p < 0.01 versus all other points at that time interval. Zx = p < 0.001 versus all 
other points. ANOVA at 72 hours: p = 0.093. n = 3 to 5 for each time point. 
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Fig. 4. Relative adhesion of  polymorphonuclear cells to HUVEC monolayers with uroldnase 
(0 to 2000 IU /ml )  or LPS (5 Ixg/ml) for 4, 24, 48, or 72 hours. Nontreated controls (0 IU /ml )  
were defined as 100%. Only LPS-stimulated HLTVECs demonstrated statistically significant in- 
creased adhesion. Zx = p < 0.001 versus all other points, § = p < 0.01 versus all other points except 
0 IU /ml  (p < 0.05 vs 0 IU/ml) .  ANOVA at 72 hours: p = 0.0514. n = 3 to 5 for each time point. 
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Fig. 5. Relative adhesion ofplatelets o HUVEC monolayers in face ofurokinase (0 to 2000 
IU/ml) or LPS (5 txg/ml) for 4, 24, 48, or 72 hours. Nontreated controls (0 IU/ml) were 
defined as 100%. Only LPS-stimulated HUVECs at 4 hours demonstrated significantly in- 
creased adhesion. A = p < 0.05 versus all other points at that ime interval, n = 3 to 5 for each time 
point. 
previously described. The remaining red blood cells 
were removed from the PMNs by incubating the 
pellet in 2 cc red blood cell lysis buffer (8.3 gm/L 
ammonium chloride in 0.01 mol /L  Tris-HC1, pH 
7.5, Sigma Chemical) for 5 minutes at 37°C fol- 
lowed by washing. Viability and cell number were 
determined for each cell type by trypan blue exclu- 
sion. PMNs, lymphocytes, and platelets were labeled 
with 51-chromium (DuPont, Boston, Mass.) by incu- 
bating cells for 1 hour at 37 ° C with 100 txCi Sl-Cr per 
5 × 106 cells. Cells were then washed with D-PBS-. 
A total of 0.5 × 106 Sl-Cr-labeled PMNs, lym- 
phocytes, or platelets added to each HUVEC well 
and incubated at 37°C for 1 hour. Nonadherent 
cells were washed free with Hank's balanced salt 
solution without Ca++ or Mg++.  HUVECs and 
adherent cells were lysed by the addition of 1.0% 
Triton X-100 (Sigma Chemical). Samples were then 
quantitated with a gamma counter. 
Adhesion molecule xpression. HUVECs were 
again plated into 6-well Primaria plates at 0.2 X 106 
cells per well in MCDB 105 and 10% FCS. Urokinasc 
(0 to 2000 IU/ml)  or LPS (5 txg/ml) was added, 
and the plates were incubated for 4, 24, or 48 hours 
as described previously. In addition, some samples 
were done with both LPS at 5 ~g/ml  and urokinase 
at 2000 IU/ml .  HUVECs were again harvested and 
washed with MCDB 105 and 10% FCS followed by 
standard azide buffer (98 cc D-PBS- ,  1 cc 10% 
sodium azide, and 1 cc FCS, pH 7.15 to 7.25). 
Either monoclonal mouse antihuman VCAM-I 
(Genzyme, Cambridge, Mass.), mouse antihuman 
ELAM-1 (Biodcsign International, Kennebunk, 
Maine), or phycoerythrin conjugated mouse antihu- 
man ICAM-1 (Biosource International, Camarillo, 
Calif.) (1.0 txg per 1.0 × 106 HUVECs) was added 
to each pellet. In addition, isotype control samples at 
the same concentration were used for each antibody 
(Sigma, St. Louis, Mo.). After 15 minutes in an ice 
bath HUVECs were washed with SAB. Because the 
anti-VCAM-1 and anti-ELAM-1 did not have 
flourochrome labeling, these cells were then incu- 
bated with fluorescein isothiocyanate-conjugated 
sheep antimouse immunoglobulin G antibody (Bio- 
design International, Kcnnebunk, Me.) and washed 
again with SAB. Each sample was resuspended in a 
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Big. 6. Absolute percent of HUVECs with positive ICAM-1 labeling after 4, 24, or 48 hours 
ofurokinase incubation. There was no significantly increased expression of ICAM-1 over that of 
urokinase nontreated control (0 IU/ml) compared with any urokinase concentration at any 
time tested. LPS stimulation at 5 I~g/mL (used as positive control) was significantly elevated 
(p -< 0.01) at all time points compared with all urokinase concentrations te ted. Percent positive 
cells at 4, 24, or 48 hours of LPS stimulation were 49.8%, 95.3%, and 93.9%, respectively (n = 
6). 
total of 200 ixL SAB, followed by the addition of 200 
Ixl 2% paraformaldehyde. 1°,34 Samples were run on 
an EPICS Profile flow cytometer (Coulter Immunol- 
ogy, Hialeah, Fla.). The lower limit for positive stain- 
ing was set not to exceed 2% as determined by the 
isotype antibody. 
Statistical analysis. All data are represented as 
the mean + SEM. Analysis of variance was per- 
formed followed by Dunnett's posttest for both 
growth and viability experiments and adhesion mol- 
ecule determinations. Student-Newman-Keuls post- 
test was used for the adhesion assay experiments. A p 
value less than 0.05 was considered significant. 
RESULTS 
HUVEC viability and growth. Fig. 1 demon- 
strates the effects of urokinase on endothelial cell 
viability at urokinase doses of 0, 500, 1000, 2000, 
5000, and 10,000 IU/ml .  After only 24 hours a 
cytopathic effect may be seen at the supratherapeutic 
uroldnase dose of 10,000 IU/ml .  By day 4 this effect 
was evident down to 2000 IU /ml  but did not signif- 
icantly affect cells at what is believed to be the clini- 
cally relevant concentrations of ---500 IU/ml .  This 
effect was also suggested by the endothelial cell 
growth curve (Fig. 2). Although statistical signifi- 
cance was not reached for the prolonged doubling 
time at uroldnase concentrations of 2000 IU/ml ,  
this appears to be due to the cytopathic effect causing 
a wide variability in doubling times at higher concen- 
trations. In fact, doubling times were not able to be 
calculated for 5000 and 10,000 IU /ml  because the 
cell number actually decreased over time. 
HUVEC/ leukocyte  adhesion. Because of the 
variability in absolute adhesion seen between differ- 
ent whole blood donors, the data were standardized 
by expressing all samples as percent of nontreated 
control (0 IU /ml  urokinase), thus giving relative 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 3 Rhodes, Tilberg, and Gifl:ord 477 
g 
I¢ M 
- -0  
J¢ E-- I= 
Nm 
o 
o 
24 
48 
Urokinase Conc: 
• 0 IU/ml 
I-I 250 
[ ]  500 
• looo 
• 2000 
0.0% 5.0% 10.0% 15.0% 
Absolute % ELAM-1 positive cells 
Fig. 7. Absolute percent of HUVECs with positive ELAM-1 labeling after 4, 24, or 48 hours 
of urokinase incubation. There was no significantly increased expression of ELAM-1 over that 
ofnontreated urokinase control (0 IU/ml) compared with any urokinase concentration at any 
time tested. LPS stimulation at 5 Ixg/ml (used as positive control) was significantly elevated 
(p --- 0.05) at 4, 24, and 48 hours compared with all urokinase concentrations tested. Percent 
positive cells at 4, 24, or 48 hours of LPS stimulation were 61.5%, 14.6%, and 8.2%, respectively 
(n = 6, except 48 hours were n = 4). 
Table I. HUVECVCAM-1 expression after 
LPS stimulation (5 Ixg/ml) (expressed as 
absolute percent of cells with positive 
VCAM- 1 staining) 
Duration of stimulation 
Urokinase 
concentration: 4 Hours 24 Hours 48 Hours 
0 IU /ml  4.9 + 0.5 37.8 + 8.8 27.8 + 4.6 
2000 IU /ml  5.5 _+ 1.0 40.8 + 7.9 28.1 + 5.2 
Data represent the mean + SEM (n = 3). p = NS by Student's 
unpaired t test for 0 versus 2000 IU/ rn l  at each time point. 
Table II. HUVEC ELAM-1 expression 
after LPS stimulation (5 ~g/ml)  (expressed 
as absolute percent of  cells with positive 
ELAM- 1 staining) 
Duration of stimulation 
Urokinase 
concentration 4 Hours 24 Hours 48 Hours 
0 IU /ml  57.7 + 12.9 12.0 _+ 4.8 4.5 + 1.6 
2000 IU /ml  65.4 + 13.7 17.3 + 10.3 11.9 + 5.3 
Data represent the mean + SEM (n = 3 for 4 and 24 hours, n = 2 
for 48 hours), p = NS for 0 versus 2000 IU /ml  at each time point. 
adhesion. Only samples treated with LPS demon- 
strated significantly increased adhesion (Figs. 3, 4, 
and 5). Incubating endothelial cells with urokinase at 
250, 500, 1000, or 2000 IU /ml  did not significantly 
increase adhesion for lymphocytes, PMNs, or plate- 
lets at any time point tested. The analysis of  variance 
did not reach significance for any of  the 72-hour 
assays, with the p values being 0.09, 0.051, and 0.78 
for lymphocytes, PMNs, and platelets, respectively. 
Although there was a trend upwards in adhesion at 
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Fig. 8. Absolute percent of HUVECs with positive VCAM-1 labeling after 4, 24, or 48 hours 
ofuro!dnase incubation. There was no significantly increased expression of VCAM-1 over that 
ofnontreated uroldnase controls (0 IU/ml) compared with any urokinase concentration at any 
time tested. LPS stimulation at 5 txg/ml (used as positive conu-ol) was significantly elevated 
(p --- 0.01) at all time points compared with all uroldnase concentrations te ted. Percent positive 
cells at 4, 24, or 48 hours of LPS stimulation were 5.2%, 39.3%, and 27.9%, respectively (n= 6). 
Table I I I .  HUVEC ICAM-1 expression 
after LI'S stimulation (5 txg/ml) (expressed 
as absolute percent of cells with positive 
ICAM-1 staining) 
Duration of stimulation 
Urokinase 
concentration 4 Hours 48 Hours 
0 IU /ml  54.2 ± 12.7 93.7 ± 1.7 
2000 IU /mt  45.3 ± 16.1 94.1 ± 1.3 
Data represent the mean _+ SEM (n = 3). p = NS for 0 versus 
2000 IU /ml  at each time point. 
the higher urokinase concentrations, this was not 
statistically significant and may be related to a VEC 
cytopathic effect. 
Adhesion molecule expression. To determine 
whether the previously mentioned trend towards in- 
creased adhesion was a biologic phenomenon, assays 
of adhesion molecules were obtained as a potentially 
more sensitive indicator of this process. HUVECs 
demonstrated constitutive xpression of ICAM-1, 
which was unaffected by uroldnase (Fig. 6). ELAM-1 
labeling did not increase over the isotype labeling, 
indicating that it is not expressed on the HUVEC 
cell surface without stimulation. Urokinase did not 
stimulate HUVECs to increase ELAM-I expression 
(Fig. 7). VCAM-1 had some minor constitutive x- 
pression but was also not increased by urokinase 
(Fig. 8). Tables I, II, and III demonstrate hat the 
proteolytic activity of urokinasc at 2000 IU /ml  did 
not decrease the expression of the various adhesion 
molecules on LPS-stimulated HUVECs. 
D ISCUSSION 
Vascular endothelial cells play an important role 
in the local inflammatory processes that are believed 
to be related to the early steps leading to neointimal 
hyperplasia and atherosclerosis. By expressing surface 
adhesion molecules, VECs are able to recruit PMNs, 
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lymphocytes, and platelets to damaged or diseased 
portions of vessels, -s,14a6 There are various stimuli 
for initiation of this local inflammatory process. For 
example, thrombin has been shown to stimulate leu- 
kocyte adhesion37,1s During arterial thrombosis 
thrombin probably plays a role in perpetuating the 
inflammatory process occurring acutely at an already 
diseased segment of vessel. 
Experimental data with urokinase have shown 
that it plays an active role in local vascular processes 
including assisting in endothelial cell migration over 
wounded areas. 26 It has also been shown to be up- 
regulated by some common proinflammatory c to- 
kines. 2<2s The previous observations have been 
made for endogenously produced urokinase at rela- 
tively low concentrations. Until now any possible 
effects of exogenously administered uroldnase for the 
treatment ofthromboembolic arterial disease at clin- 
ically relevant doses was unknown. 
Data obtained from Abbott Laboratories (Abbott 
Laboratories, Abbott Park, Ill.) indicated that 500 
IU /ml  was the concentration required to gain max- 
imal plasminogen activation. The clinical urokinase 
dosing protocols were arrived at in part by adjusting 
dosing to maximal thrombolysis, 2 which would oc- 
cur at approximately 500 IU /ml  in our model. Mso, 
considering that the proteolytic half life is 10 to 20 
minutes in vivo 29 and assuming some minimal mix- 
ing of blood components in the area of the thrombus 
and the fact that the VECs in this area are covered by 
thrombus, the actual dose to which the VECs are 
exposed is probably less than what is required for 
maximal thrombolysis. 
Our initial studies examined the dose-dependent 
effect that urokinase has on HUVEC viability and 
growth. Although we were not able to calculate dou- 
bling times for the 5000 and 10,000 IU /ml  points 
because of the decrease in cell number, we believe 
this reflects uprapharmacologic cytopathic effect. A 
more important observation was that urokinase doses 
up to 1000 IU /ml  showed no statistical differences 
in either viability or growth. The remainder of the 
experiments were performed to urokinase concentra- 
tions of 2000 IU /ml  to avoid focusing on effects at 
clinically irrelevant dosages. 
Urokinase did not upregulate invitro adhesion of 
PMNs, lymphocytes, or platelets to HUVECs. In 
separate xperiments urokinase failed to increased 
ELAM-1, VCAM-1, or ICAM-1 expression, adding 
further support o the adhesion assay results. When 
adding urokinasc to maximally LPS stimulated cells, 
we were unable to show any beneficial effect that 
urokinasc could havc theoretically exerted on the 
VECs by its proteolytic actions on cell surface adhe- 
sion molecules. 
The in vitro results demonstrate hat exogenously 
administered urokinase at dosages used for clinical 
thrombolysis does not affect VEC adhesion molecule 
expression or leukocyte/platelet adhesion and thus 
does not upregulate the vascular endothelial cell me- 
diated inflammatory esponse. Although one cannot 
conclude the effects are identical in vivo, the lack of a 
proinflammatory esponse in this in vitro setting 
makes it unlikely that upregulation would occur in 
vivo. 
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